Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | MME | P08473 | 7/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.42 |
| ▸ | ACE | P12821 | 4/20 | 0.42 |
| ▸ | CPA1 | P15085 | 3/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21417606 | 0.87 | FPR2 (0.46) | FPR2PPARGMMEACE2ACE | |
| SCHEMBL25101017 | 0.84 | FPR2 (0.44) | FPR2L3MBTL1 | |
| SCHEMBL31754326 | 0.83 | ADRA2A (0.51) | — | |
| SCHEMBL13881444 | 0.81 | ALB (0.47) | FPR2PPARGMMEACE2ACE | |
| SCHEMBL20816437 | 0.81 | ALB (0.47) | FPR2PPARGMMEACE2ACE | |
| SCHEMBL161943 | 0.81 | FOLH1 (0.60) | MMEACE2ACECPA1FOLH1 | |
| SCHEMBL160418 | 0.81 | FOLH1 (0.60) | MMEACE2ACECPA1FOLH1 | |
| SCHEMBL22444653 | 0.81 | PPARG (0.47) | PPARGMMEACE2ACECPA1 | |
| SCHEMBL9886036 | 0.81 | TDP1 (0.55) | PPARGMMEACE2ACECPA1 | |
| SCHEMBL805206 | 0.81 | TDP1 (0.55) | PPARGMMEACE2ACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120071329-A1 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | GLAXOSMITHKLINE (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989395-B2 | Methods for identifying compounds of interest using encoded libraries | GLAXOSMITHKLINE LLC (US) | 2011-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251089-A1 | METHODS FOR SYNTHESIS OF ENCODED LIBRARIES | RNGTT, DTYMK, DUT | FPR2 1900/4885PPARG 4377/4885MME 562/4885 |
| US-20120251459-A1 | SPECIFIC INHIBITORS AND ACTIVE SITE PROBES FOR LEGUMAIN | ENGASE, LGMN, DNPEP | FPR2 3899/4885PPARG 4800/4885MME 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.